US › Healthcare

Jasper Therapeutics Inc (JSPR)

US · Healthcare · Biotechnology

$0.63+9.12%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-2.8M

EPS

$-0.24

EPS estimate

$-0.37

EPS came in at -0.24 against a street estimate of -0.37 — a beat of 35.1%.

Key statistics

Market cap

$22.0M

Forward P/E

0.0

P/B

15.54

Book value

$0.05

EPS (TTM)

$-0.93

52-week high

$2.69

52-week low

$0.32

50-day MA

$0.69

200-day MA

$1.06

Beta

3.04

Analyst view

Analysts rate Jasper Therapeutics Inc a strong buy (11 buy, 0 hold, 0 sell out of 11) with an average price target of $7.38.

Shareholding

Insiders

2.87%

Institutions

39.50%

Largest institutional holders

Fund	Stake
Velan Capital Investment Management LP	8.02%
Kingdon Capital Management LLC	4.06%
Morgan Stanley - Brokerage Accounts	4.01%
Vanguard Capital Management, LLC	3.52%
Rock Springs Capital Management LP	3.31%
The Carlyle Group Inc	3.20%
BOOTHBAY FUND MANAGEMENT, LLC	1.75%
GSA Capital Partners LLP	1.61%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Jasper Therapeutics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.